Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance
2024

Effects of Ivacaftor on Staphylococcus aureus in Cystic Fibrosis

Sample size: 11 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bollar Gretchen E, Shaffer Kendall M, Keith Johnathan D, Oden Ashley M, Dowell Alexander E, Ryan Kevin J, Acosta Edward P, Guimbellot Jennifer S, Kiedrowski Megan R, Birket Susan E

Primary Institution: University of Alabama at Birmingham

Hypothesis

Does exposure to ivacaftor lead to the formation of small colony variants (SCVs) of Staphylococcus aureus that are more tolerant to antibiotics?

Conclusion

Ivacaftor treatment did not reduce the bacterial burden of Staphylococcus aureus in cystic fibrosis rats and led to the formation of antibiotic-tolerant SCVs in vitro.

Supporting Evidence

  • Ivacaftor did not significantly reduce S. aureus burden in the lungs of treated rats.
  • Approximately 25% of bacteria recovered from ivacaftor-treated rats exhibited the SCV phenotype.
  • The study showed that ivacaftor exposure led to the formation of antibiotic-tolerant SCVs in vitro.

Takeaway

The study found that a drug called ivacaftor doesn't help get rid of a germ called Staphylococcus aureus in the lungs of people with cystic fibrosis, and it might even help the germ become tougher.

Methodology

The study used humanized G551D-CFTR rats treated with ivacaftor for 7 days, measuring bacterial survival and SCV formation in vitro.

Limitations

The study was conducted in a rat model, which may not fully replicate human responses.

Participant Demographics

Humanized G551D-CFTR rats, both male and female, over 6 months of age.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/jacamr/dlae185

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication